Cabergoline

證據等級: L5

預測適應症: 10 個

Cabergoline: From Prolactinoma to Pituitary Cancer

One-Sentence Summary

Cabergoline is a selective dopamine D2 receptor agonist, established globally as the first-line treatment for prolactin-secreting pituitary adenomas (prolactinoma) and hyperprolactinemia, though it is not currently registered in Singapore. The TxGNN model predicts it may be effective for Pituitary Cancer — including non-functioning pituitary adenomas (NFPA) and corticotroph adenomas causing Cushing's disease — with 19 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not registered in Singapore; globally established for prolactinoma / hyperprolactinemia
Predicted New Indication	Pituitary Cancer (non-functioning pituitary adenoma; corticotroph adenoma / Cushing's disease)
TxGNN Prediction Score	99.04%
Evidence Level	L1
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Cabergoline is a selective dopamine D2 receptor (D2R) agonist. Its primary mechanism in prolactinoma is direct activation of D2R expressed on lactotroph tumor cells, which suppresses prolactin hypersecretion and induces tumor cell apoptosis and measurable shrinkage. For decades, it has been the undisputed first-line medical therapy for prolactinoma. Formal MOA documentation (DrugBank) was not available in the current evidence pack, so this mechanistic description is reconstructed from the clinical literature.

The repurposing rationale is mechanistically grounded: D2R expression is not exclusive to prolactin-secreting tumors. Non-functioning pituitary adenomas (NFPAs) — the most surgically challenging subtype and the one with no approved medical therapy — also express D2R at variable levels, and D2R-positive NFPAs respond to cabergoline with measurable tumor volume reduction. Similarly, corticotroph adenomas (the cause of Cushing's disease) express D2R, and cabergoline suppresses pathological ACTH secretion through this receptor. Beyond receptor-level effects, newer research has revealed non-dopaminergic anti-tumor mechanisms: cabergoline induces autophagy, inhibits cell proliferation via PI3K/mTOR pathways, and synergizes with chloroquine to enhance pituitary tumor cell death across multiple subtypes.

From a clinical evidence standpoint, the case for pituitary cancer is already substantiated: one completed Phase 3 RCT in NFPA (NCT03271918, n=140), one completed Phase 3 trial in Cushing's disease (NCT00889525), a 2022 systematic review and meta-analysis confirming NFPA benefit (PMID 35902444), and multiple international guidelines endorsing its use across pituitary tumor subtypes. Evidence reaches L1 for prolactinoma (standard of care) and L2 for NFPA and corticotroph adenomas. The TxGNN prediction is strongly supported by the existing literature.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00889525	Phase 3	Completed	N/A	Direct study of cabergoline efficacy in Cushing's disease (corticotroph adenoma); based on D2R expression confirmed in in vitro studies of corticotroph tumor cells; assessed cortisol normalization with oral cabergoline
NCT03271918	Phase 3	Completed	140	RCT of cabergoline in residual NFPA after transsphenoidal surgery; evaluated tumor volume control versus no treatment — the largest completed cabergoline RCT in NFPA to date
NCT07034859	Phase 4	Enrolling by Invitation	30	Randomized 1:1 trial of cabergoline vs. observation as primary therapy for NFPA over 48 weeks; assesss tumor size reduction as primary endpoint in treatment-naïve patients
NCT02288962	Phase 3	Active, Not Recruiting	60	RCT of dopamine agonist treatment for NFPA not yet requiring surgery; evaluates growth prevention, surgical delay, and preservation of pituitary function
NCT01915303	Phase 2	Terminated	68	Pasireotide alone or combined with cabergoline for Cushing's disease; assessed whether dual somatostatin + dopamine receptor targeting produces additive efficacy in corticotroph adenomas
NCT00376064	Phase 4	Completed	20	Octreotide + cabergoline combination in acromegaly partially resistant to somatostatin analog monotherapy; explored additive GH suppression through concurrent D2R targeting
NCT03714763	N/A	Unknown	50	PET-MR imaging of dopamine D2 receptors in NFPA; investigates whether in vivo D2R expression predicts cabergoline treatment response — a patient-selection biomarker study
NCT01620138	Phase 2/3	Completed	21	Somatostatin and dopamine receptor expression in NFPA and resistant prolactinomas; correlated receptor levels by mRNA and immunohistochemistry with in vitro and in vivo response to cabergoline
NCT03400865	N/A	Unknown	30	Cabergoline combined with hydroxychloroquine/chloroquine for cabergoline-resistant prolactinomas; based on autophagy-mediated synergy demonstrated in preclinical models
NCT01143584	N/A	Unknown	20	Rapid vs. conventional cabergoline dose escalation in macroprolactinomas; explored whether faster titration achieves earlier prolactin normalization and tumor shrinkage, potentially reducing cumulative dose

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35902444	2022	Meta-analysis	Pituitary	Systematic review and meta-analysis of cabergoline in NFPA; quantified tumor stabilization and shrinkage rates across multiple studies — provides the highest-quality summary evidence for NFPA
37097352	2023	Review	JAMA	Comprehensive review of pituitary adenoma diagnosis and management; dopamine agonists cited as standard medical therapy; covers both functioning and non-functioning tumor subtypes
36974474	2023	Review	J Clin Endocrinol Metab	Clinical approach to prolactinoma; cabergoline as current gold-standard first-line treatment with high remission rates; discusses resistance and special populations
36013562	2022	Review / Guideline	Medicina	Historical and modern management of prolactinomas including aggressive subtypes; reviews evidence base for dopamine agonists and multimodality options for resistant prolactinomas
37171003	2023	Guideline	Endocr Metab Immune Disord Drug Targets	Italian national guidelines for prolactinoma management; defines cabergoline dosing targets, monitoring protocols, and criteria for treatment withdrawal
38989697	2024	Translational	Neuro-oncology	HTR2B suppression enhances NFPA sensitivity to cabergoline via inhibition of the Gαq/PLC/PKCγ/STAT3 axis; identifies a novel combination target to overcome cabergoline resistance in NFPA
25732645	2015	Review	Endocrinol Metab Clin North Am	Cabergoline safety and efficacy across pituitary tumor types; cardiac valvular risk reviewed — not significantly elevated at standard endocrine doses compared with Parkinson's-level cumulative doses
28973192	2017	Experimental	J Clin Endocrinol Metab	Cabergoline + chloroquine combination suppresses pituitary tumor growth in vitro and in vivo via autophagy induction; overcomes resistance in prolactinomas and extends activity to other adenoma types
31597135	2020	Review	Neuroendocrinology	Novel anti-tumor mechanisms of cabergoline beyond the D2R pathway: anti-proliferative, pro-apoptotic, and autophagy effects in NFPA, corticotroph, and somatotroph adenomas
39891847	2025	Research	J Neuro-oncol	NDFIP1 upregulation activates mTOR signaling as a cabergoline resistance mechanism in pituitary neuroendocrine tumors; provides rationale for combining cabergoline with mTOR inhibitors

Singapore Market Information

Cabergoline has no registered products in Singapore (0 HSA authorizations on record). Patients requiring cabergoline would need access through special drug import channels subject to HSA approval.

Safety Considerations

Please refer to the package insert for safety information.

Note from clinical literature: Although formal safety data was unavailable in this evidence pack, two clinically important adverse effect categories are well-documented in the published literature and should be proactively managed:

Impulse control disorders (ICDs): Pathological gambling, hypersexuality, compulsive shopping, and related compulsive behaviors have been reported in patients on dopamine agonist therapy, with prevalence reported up to 59.8% in some series. Routine ICD screening using a validated tool is strongly recommended at each follow-up visit.

Cardiac valvular risk: Long-term high cumulative doses are associated with valvular regurgitation (a class effect of ergot-derived dopamine agonists). Echocardiographic baseline assessment and periodic monitoring are recommended, particularly when cumulative weekly doses exceed 3 mg.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic basis for cabergoline use across pituitary tumor subtypes is well-established via the D2R pathway, supported by two completed Phase 3 trials, a systematic review and meta-analysis, and multiple international guidelines. Evidence reaches L1 for prolactinoma (already standard of care) and L2 for NFPA and corticotroph adenoma — making this one of the strongest repurposing signals in the evidence pack, with a clearly defined patient population and measurable clinical endpoints.

To proceed, the following is needed:

HSA special import approval or initiation of formal product registration for cabergoline in Singapore
Complete package insert (MOA, warnings, contraindications, DDI profile) sourced from DrugBank or originator manufacturer
D2R expression testing protocol to guide patient selection, especially for NFPA (as explored in NCT03714763)
Baseline and follow-up echocardiography plan for cardiac valvular surveillance
Impulse control disorder (ICD) screening tool integrated into routine endocrinology follow-up visits
Subtype-specific dosing protocol: NFPA and corticotroph adenoma dosing strategies are distinct from the prolactinoma protocol and require separate clinical guidance
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.